Elliott Pauli is a project manager with 15 years of performance in Pharmaceutical R&D. His expertise and working knowledge consist of CMC, nonclinical, clinical, and regulatory from early pre-IND to late Phase III. As a project manager for Global Health Technologies (GHT) at RTI International, he currently manages multinational teams to support the all activities for the development of experimental antimicrobials and antituberculars. He is leading the CMC efforts for Phase III antitubercular on behalf of the Global Alliance for TB Drug Development (TB Alliance). He also supports GHT with a SRI International/National Institutes of Allergy and Infectious Disease (NIAID) contract by coordinating activities associated with the assessment of antitubercular drugs being co-developed by the Lilly Initiative and their partners. Before coming to RTI, Elliot worked as a quality control/research microbiologist for Bristol Myers Squibb and Idexx Pharmaceuticals, where he applied his expertise to help establish standard operating procedures and method developments for new compounds. Elliott’s areas of technical expertise include epidemiology, TB, and microbiology. He earned his MPH from Southeastern Louisiana University.